Evry, France, Thursday October 19, 2023, 5:45 p.m. – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company of the OncoDNA group specializing in the genomics of cancer and rare genetic diseases, which carries out interpretable genomic analyzes for academic laboratories and private companies, today announces its unaudited results for the first half of 20223, the accounts having been approved by the Board of Directors on October 16, 2023.
Bernard Courtieu, Managing Director of IntegraGen, declares: “IntegraGen achieved a solid performance in the first half of 2023, restated for the drop in activity linked to COVID on the Institut Pasteur site. This drop is mainly linked to the decline in orders for reagents for the platform, which explains the limited impact on profitability.
Excluding Covid, activity in H1 2023 was sustained at the Évry laboratory and on the platform operated on behalf of GCS SeqOIA.
As part of our strategic plan, IntegraGen continued its efforts in the field of quality in order to obtain the certifications necessary for the development of the activity of services to the pharmaceutical industry for the clinical development of new drugs in oncology. These developments will carry the main growth prospects in 2024/2025. »